Company intelligence / Profile preview

Beijing Zhitai Biomedical Technology

Beijing, Beijing Shi, Chinadnb.com ↗

Ownership: Private
Development stage: Other

Overview

Beijing Zhitai Biomedical Technology has a pipeline focused on metabolic and nervous system diseases. Its lead asset appears to be a semaglutide biosimilar for obesity currently in Phase 2. Other assets include GLP-1R-targeting drugs for Alzheimer disease (Phase 1) and obesity (Phase 1), as well as preclinical programs for diabetes mellitus. The company leverages recombinant polypeptide/protein technologies and fusion proteins but does not appear to have first-in-class or novel mechanisms at this time.

Therapeutic areas: EndocrinologyNeurology
Modalities: Recombinant polypeptideRecombinant proteinFusion proteinBiosimilar
Industry: Biotech

Drug pipeline

1 asset

ZT006

Beyond the preview

Go deeper on Beijing Zhitai Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Zhitai Biomedical Technology.

Explore the full profile